Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
13 December 2021 |
Main ID: |
EUCTR2018-004392-12-FR |
Date of registration:
|
13/05/2019 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A study to assess long-term safety, tolerability and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy
|
Scientific title:
|
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Date of first enrolment:
|
10/09/2019 |
Target sample size:
|
34 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004392-12 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: Placebo: Other:
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Canada
|
Denmark
|
France
|
Germany
|
Netherlands
|
Spain
|
United Kingdom
|
United States
| | | | | | | |
Contacts
|
Name:
|
Clin Trial Reg & Results Disclosure
|
Address:
|
Alfred-Nobel-Strasse 10
40789
Monheim
Germany |
Telephone:
|
|
Email:
|
clinicaltrials@ucb.com |
Affiliation:
|
UCB BIOSCIENCES GmbH |
|
Name:
|
Clin Trial Reg & Results Disclosure
|
Address:
|
Alfred-Nobel-Strasse 10
40789
Monheim
Germany |
Telephone:
|
|
Email:
|
clinicaltrials@ucb.com |
Affiliation:
|
UCB BIOSCIENCES GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Subject who has completed one of the previous rozanolixizumab study(ies) that allow access to the present study (e.g. study CIDP01) - Female subjects of childbearing potential must agree to use a highly effective method of birth control, during the study and for a period of 3 months after their final dose of investigational medicinal product (IMP) - Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active during the study and for 3 months after the final administration of IMP Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 26 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 8
Exclusion criteria: - Subject has any medical (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could harm the subject or would compromise the subject’s ability to participate in this study - Subject has a clinically relevant active infection (eg, sepsis, pneumonia, abscess) - Subject has a known hypersensitivity to any components of rozanolixizumab - Subject intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of rozanolixizumab - Subject has an ongoing serious adverse event (SAE) or a medical condition in the parent study that the investigator considers to put the subject at a significantly increased risk of participating in CIDP04 - Subject has any planned elective surgery due to occur during the study dosing period which in the opinion of the investigator could interfere with study procedures
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) MedDRA version: 20.0
Level: PT
Classification code 10057645
Term: Chronic inflammatory demyelinating polyradiculoneuropathy
System Organ Class: 10029205 - Nervous system disorders
|
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
|
Intervention(s)
|
Product Name: Rozanolixizumab Product Code: UCB7665 Pharmaceutical Form: Solution for infusion INN or Proposed INN: ROZANOLIXIZUMAB Current Sponsor code: UCB7665 Other descriptive name: Rozanolixizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 140-
|
Primary Outcome(s)
|
Secondary Objective: Assess long-term clinical efficacy of doses of rozanolixizumab
|
Main Objective: Assess long-term safety and tolerability of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
|
Timepoint(s) of evaluation of this end point: From Baseline until Follow-Up Visit (up to Week 32)
|
Primary end point(s): Occurrence of treatment-emergent adverse event (TAEs)
|
Secondary Outcome(s)
|
Secondary end point(s): No secondary end points are defined.
|
Timepoint(s) of evaluation of this end point: No secondary end points are defined.
|
Secondary ID(s)
|
2018-004392-12-GB
|
CIDP04
|
Source(s) of Monetary Support
|
UCB Biopharma SPRL
|
Ethics review
|
Status: Approved
Approval date: 11/09/2019
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|